arrow
R

Robin Dewar

Frederick National Laboratory for Cancer Research
H指数:45
被引数:7,948

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Measurement of binding antibodies to SARS-CoV-2 variants elicited by natural infection and COVID-19 vaccines in a sub-Saharan African population

测量撒哈拉以南非洲人群自然感染和COVID-19疫苗接种后针对SARS-CoV-2变异株的结合抗体的检测

2026-09-020
OA
HIV-1 suppression and rare dolutegravir resistance in antiretroviral-experienced people with HIV in Liberia

HIV-1抑制及利托那韦经验丰富的利巴韦林耐药在利比里亚HIV感染者中的罕见情况

2025-05-090
OA
Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4/BA.5 mRNA booster

先前的SARS-CoV-2感染会影响对Omicron BA.4/BA.5 mRNA增强剂的适应性免疫反应

2025-03-030
PRE
Viral Burden and Illness Severity During Acute SARS-CoV-2 Infection Predict Persistent Long COVID Symptoms

急性SARS-CoV-2感染期间的病毒负担和疾病严重程度可预测持续的长期COVID症状

2025-01-300
OAAI
Pediatric SARS-CoV-2 long term outcomes study (PECOS): cross sectional analysis at baseline
2024-12-181
OAAI
Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019
2024-09-120
PRE
Severe Acute Respiratory Syndrome Coronavirus 2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With Coronavirus Disease 2019

新型冠状病毒血浆抗体和核衣壳抗原状态可预测冠状病毒病门诊患者的预后2019

2024-07-171
PRE
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir

SARS-CoV-2 RNA和核衣壳抗原是与严重疾病结局相关的血液生物标志物,对Remdesivir的反应有所改善

2024-04-243
OA
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19

中和单克隆抗体治疗对新型冠状病毒肺炎住院患者病毒学和免疫学生物标志物早期轨迹的影响

2023-11-091
OAAI
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial
2023-09-017
OAAI
Long-term persistence of transcriptionally active 'defective' HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy
AIDS
IF3.1
2023-08-0816
OAAI
Immune reconstitution inflammatory syndrome drives emergence of HIV drug resistance from multiple anatomic compartments in a person living with HIV
2023-06-156
OA
Vaccination Ameliorates Cellular Inflammatory Responses in SARS-CoV-2 Breakthrough Infections

疫苗接种可改善SARS-CoV-2突破性感染的细胞炎症反应

2023-02-188
OA
Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment

尼马来韦/利托那韦治疗后症状性冠状病毒疾病2019反弹的临床,病毒学和免疫学评估

2022-10-0635
OA
Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase atrial
2022-10-0166
OAAI
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
2022-10-0142
OA
Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with progression to severe disease in hospitalized COVID-19
2022-09-1420
OAAI
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19: A Randomized Controlled Trial
2022-09-0117
OA